---
title: "New Medicare Policies Limit Important Pain Relief Options for Patients"
id: "stat-news-1-opinion-new-medicare-policies-will-keep-important-pain-relief-from-some-patients"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-opinion-new-medicare-policies-will-keep-important-pain-relief-from-some-patients"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/10/23/severe-pain-policy-medicare-coverage-macs-nerve-block/?utm_campaign=rss"
published_at: "2026-10-23T08:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# New Medicare Policies Limit Important Pain Relief Options for Patients
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-opinion-new-medicare-policies-will-keep-important-pain-relief-from-some-patients
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/10/23/severe-pain-policy-medicare-coverage-macs-nerve-block/?utm_campaign=rss)
- **Published At:** 2026-10-23T08:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- New Medicare policies set to restrict coverage for many peripheral nerve treatments. - Policy changes affect millions with severe chronic pain. - The modifications, while less restrictive than the previous proposal, still hinder access to effective pain management strategies. - Peripheral nerve blocks have previously provided significant relief for patients, impacting quality of life. - Concerns exist regarding the quality of evidence supporting these procedures, but subjective patient experiences challenge strict evidence models. - Advocates call for a balanced approach that ensures access while addressing evidence gaps in chronic pain treatment.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/10/23/severe-pain-policy-medicare-coverage-macs-nerve-block/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/23/severe-pain-policy-medicare-coverage-macs-nerve-block/?utm_campaign=rss) [Cancer](https://www.statnews.com/topic/cancer/) [rare diseases](https://www.statnews.com/topic/rare-diseases/) [ethics](https://www.statnews.com/topic/ethics/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) Opinion[First Opinion](https://www.statnews.com/category/first-opinion/) # New Medicare policies will keep important pain relief from some patients ## Have we learned nothing from the opioid epidemic? * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/23/severe-pain-policy-medicare-coverage-macs-nerve-block/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/10/AP17047735669828-645x645.jpg) Patrick Semansky/AP By Antje M. Barreveld Oct. 23, 2026 Barreveld is chief of pain medicine and an anesthesiologist at Newton-Wellesley Hospital (Mass General Brigham), associate professor of anesthesiology at Tufts School of Medicine, and immediate past president of the American Academy of Pain Medicine. For years, one of my patients lived with chronic pelvic pain that felt like a hot poker in her vagina. After I performed a targeted nerve block with numbing medication, her pain disappeared. Through tears, she told me something I have heard from patients again and again: “I forgot what it’s like to not have pain. Thank you.” A peripheral nerve block delivers numbing medication around a nerve to interrupt pain signals. It can help identify the source of pain and, for some patients, provide relief that lasts well beyond the few hours before the numbing effect wears off. Advertisement But beginning in late October, new [Medicare policies](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=40267&ver=6) issued by five regional Medicare Administrative Contractors (MACs) — which determine local oversight of 37 states and several U.S. territories — will restrict coverage for millions of patients with severe pain, including my patients, by cutting access to many peripheral nerve procedures used to diagnose and treat chronic pain. The Centers for Medicare and Medicaid Services writes and oversees the Medicare rules. But because Medicare claims are so big, [MACs are private companies](https://www.cms.gov/medicare/coding-billing/medicare-administrative-contractors-macs/whats-mac) that operate much of the machinery to apply those rules to individual health care providers and claims. The [final policy is slightly less restrictive](https://academic.oup.com/painmedicine/article-abstract/27/8/863/8494528?redirectedFrom=fulltext) than the [proposal released in 2025](https://www.statnews.com/2025/10/31/medicare-coverage-peripheral-nerve-block-procedures/), an important response to patients, physicians, and advocates who spoke up. But it still leaves patients with high-impact chronic pain at risk of losing access to treatments used for decades in pain care that can restore something as basic as the ability to sleep, go out and buy groceries, or spend hours every day without being consumed by pain. Advertisement Related Story ![](https://www.statnews.com/wp-content/uploads/2024/05/AdobeStock_357630467-768x432.jpeg) ### [Treating chronic pain requires much more than medications](https://www.statnews.com/2024/05/16/chronic-pain-treatment-requires-more-than-medications/) The final policy excludes therapeutic procedures targeting nerves such as the pudendal nerve and ganglion impar, interventions used for some forms of severe pelvic pain. I have used these interventions to provide relief to patients who previously never had a break from pain, people for whom sitting, putting on a pair of pants, having sex, or simply getting through the day can be excruciating. As a pain medicine physician, I worry that we are forgetting one of the central lessons of the opioid epidemic: People with chronic pain need alternatives to opioids and more individualized treatment options. Peripheral nerve interventions are not used in isolation. They are part of multimodal and multidisciplinary pain care, helping patients participate in physical therapy, restore function, decrease medications, avoid emergency room visits and hospitalizations, and sometimes delay or avoid more invasive procedures or surgery. CMS contractors have a legitimate concern. In evaluating these procedures, they point to limitations in the evidence, including small studies, short follow-up periods, and uncertainty about whether benefits last. For several procedures, they concluded that the evidence was insufficient to support coverage. But chronic pain presents a particular challenge for this style of evidence gathering. Pain is [by definition](https://www.iasp-pain.org/publications/iasp-news/iasp-announces-revised-definition-of-pain/#:~:text=The%20definition%20is%3A%20%E2%80%9CAn%20unpleasant,associated%20with%2C%20actual%20or%20potential) a subjective experience, and every patient experiences pain differently. A treatment that produces limited benefit on average across a study population may provide profound relief to an individual. Population-level evidence matters, but it cannot always capture which patients experience a clinically meaningful benefit. And for the [1 in 4 U.S. adults living with unrelenting pain](https://www.cdc.gov/nchs/products/databriefs/db518.htm), even a few weeks or months of decreased suffering can help them feel like themselves again. My mother taught me that long before I became a pain physician. She is a brilliant cancer research scientist who has lived with chronic migraine and abdominal pain and, like so many patients I now see, often struggles to find physicians who understand her pain or know how to help her. She inspires me to keep looking for answers for patients who have spent years doing the same. Advertisement One of them was a remarkably healthy 87-year-old with severe bladder pain. By the time she came to see me, she had been passed from one doctor to another and was in despair. “I see it in their eyes,” she told me. “They don’t know what to do with me, and they look like they are trying to leave the room. I’ve never felt this way; people always want to be close to me.” In my clinic, I meet patients no one knows how to help. And sometimes, the procedures I perform can be life-changing. Some may question whether these procedures are used too often, whether the evidence supporting them is strong enough, or whether financial incentives influence their use. Those are fair questions. Not every nerve block works, and Medicare should not pay indefinitely for treatments that do not help. We need better evidence, including larger studies, longer-term patient follow-up, and federal funding to support this research. The answer to gaps in evidence is to seek that real-world evidence while at the same time preserving appropriate access to effective non-opioid treatments But absence of perfect evidence should not be confused with absence of meaningful patient benefit. One of my patients developed chronic pain after gynecologic surgery. After a pudendal nerve block, she told me: “I did not realize how different my life was because of the pain until you gave me the injection that took my pain away. I was able to wear pants, sit in a chair, and spend my day without being distracted by horrible pain.” That may sound like a modest victory. To someone living with chronic pain, it is anything but. In a few weeks, this pain relief will no longer be accessible to her. Individualized pain care should not depend on luck, who you know, your insurance coverage, or what is in your checking account. Pain does not always fit neatly into an insurance box of “approve” or “deny.” Effective pain care requires a [broad treatment toolkit](https://www.statnews.com/2024/05/16/chronic-pain-treatment-requires-more-than-medications/). That toolkit is meaningless if patients cannot access it. Advertisement As these new policies take effect, Medicare contractors must reconsider restrictions as new evidence emerges, while researchers, clinicians, and specialty societies build and identify funding for the larger, longer-term studies Medicare says it needs. We need coverage standards that recognize clinically meaningful benefit while continuing to demand better evidence. We should not put the tools physicians use to relieve suffering out of patients’ reach. _Antje M. Barreveld is chief of pain medicine and anesthesiologist at Newton-Wellesley Hospital (Mass General Brigham) in Newton, Mass.; associate professor of anesthesiology at Tufts School of Medicine; and immediate past president of the American Academy of Pain Medicine._ * * * ###### Letter to the editor Have an opinion on this essay? [Submit a letter to the editor](https://www.statnews.com/submit-a-letter-to-the-editor/?subject=New%20Medicare%20policies%20will%20keep%20important%20pain%20relief%20from%20some%20patients). [CMS](https://www.statnews.com/topic/cms/), [Medicare](https://www.statnews.com/topic/medicare/), [pain](https://www.statnews.com/topic/pain/), [patients](https://www.statnews.com/topic/patients/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. Antje M. Barreveld 1. [](https://x.com/AntjeBarreveld "X") 2. [](https://www.linkedin.com/in/antje-barreveld "Linkedin") 1. [](https://x.com/AntjeBarreveld "X") 2. [](https://www.linkedin.com/in/antje-barreveld "Linkedin") ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/First-Opinion-Logo-Black-640x319.png) ### Newsletter The smartest thinkers in life sciences on what's happening — and what's to come Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2025/05/AdobeStock_525738206_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) 2. ![](https://www.statnews.com/wp-content/uploads/2024/11/DSC09995-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Alnylam says Huntington’s drug shows promise in early study](https://www.statnews.com/2026/10/23/huntingtons-alnylam-gene-silencing-brezosiran/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/Andrea-Carol-Miranda-in-Medford-1990-80x80.jpg) [The inherited disease my family called ‘it’ had a name, which changed everything](https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/10/https___cdn.sanity.io_images_xq1bjtf4_production_964fa47326a827f12bf336e880b2fdc4665711e6-5973x4480-1-80x80.jpg) [I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lying](https://www.statnews.com/2026/10/19/elizabeth-holmes-theranos-whistleblower-tyler-shultz-insider-review/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_514511258-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations ](https://www.statnews.com/2026/10/22/abbvie-lutikizumab-hidradenitis-suppurativa-drug-phase-3-results/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/TevaPF_Wordpress_CalendarImage-80x80.jpg) The Next Era of Biosimilars: Rewriting the Playbook Virtual Oct 19 ](https://www.statnews.com/event/next-era-of-biosimilars-rewriting-the-playbook/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/ESMORecap_Wordpress_CalendarImage-80x80.jpg) ESMO 2026: The STAT Recap Virtual Oct 29 ](https://www.statnews.com/event/esmo-2026-the-stat-recap/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2025/07/GettyImages-2208174977-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In DOGE’s aftermath, federal health workers bristle at new performance reviews](https://www.statnews.com/2026/10/16/federal-performance-reviews-health-agency-employees-wary-after-doge/) 2. ![](https://www.statnews.com/wp-content/uploads/2025/05/AdobeStock_525738206_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2263715743-80x
## Related Clinical Research

- [AbbVie’s lutikizumab meets Phase 3 endpoint in hidradenitis suppurativa but falls short of market](https://medichelpline.com/clinical-feed/stat-news-1-stat-abbvie-skin-disorder-drug-succeeds-in-late-stage-trial-but-results-miss.md)
- [What to read before you see the new Elizabeth Holmes documentary](https://medichelpline.com/clinical-feed/stat-news-4-what-to-read-before-you-go-see-that-new-documentary-on-elizabeth-holmes.md)
- [Statin Use Linked to Reduced Glaucoma Risk in Recent Study](https://medichelpline.com/clinical-feed/medical-news-today-0-statins-may-help-lower-glaucoma-risk-study-finds.md)
- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.